Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Post-Diagnosis Statin Use & Mortality Risk in HCC

Clin Gastroenterol Hepatol; ePub 2019 Jan 6; Thrift, et al

Statin use after diagnosis of hepatocellular carcinoma (HCC) is associated with reduced mortality in HCC patients, a new study found. Researchers used data from 15,422 patients with HCC in the VA Central Cancer Registry diagnosed between 2002‒2016. Statin prescriptions that were filled before and after cancer diagnosis were identified, and time-dependent Cox regression models were used to calculate adjusted hazard ratios (HRs) for mortality risk. They found:

  • After diagnosis, statin use was recorded in 14.9% of HCC patients.
  • Post-diagnosis statin use was associated with a decreased risk of cancer specific (adjusted HR, 0.85) and all-cause mortality (HR, 0.89).
  • The degrees of these inverse associations were consistent for HCC patients using both low- and high-dose statins and remained across a range of lag periods (from 0-12 months after HCC diagnosis).

Citation:

Thrift AP, Natarajan Y, Lui Y, El-Serag HB. Statin use after diagnosis of hepatocellular carcinoma and patient survival: Findings from a retrospective cohort study. [Published online ahead of print January 6, 2019]. Clin Gastroenterol Hepatol. doi:10.1016/j.cgh.2018.12.046.